Treatment of Seborrheic Dermatitis in Parkinson's Disease
This protocol addresses seborrheic dermatitis (SD) occurring in a patient with Parkinson's disease — a combination that is well recognised clinically. Unilateral facial SD has frequently been observed in longstanding Parkinson's disease ("masked facies" or "hypomimia"), making this comorbidity a distinct and important clinical scenario that requires a tailored treatment approach.
Clinical Scenario
Patients with Parkinson's disease are at elevated risk for seborrheic dermatitis, particularly involving the face. The neurological condition itself is considered among the predisposing factors for SD in this population, including through effects on hygiene and skin sebum dynamics.
Treatment Approach — Summary
The approach for this population centres on topical antifungal and antiinflammatory agents applied to affected areas, combined with appropriate skin cleansing measures. An important consideration specific to Parkinson's patients affects which systemic options can and cannot be used.
The full regimen — including specific agents, sequencing, and any additional guidance for this population — is detailed in the structured protocol.
References
DOI: 10.2147/CCID.S284671
- In particular, unilateral facial SD has frequently been observed in longstanding Parkinson's disease ("masked facies" or "hypomimia") as well as in subjects with paralysis occurring after cerebrovascular accidents.
- The mainstay of SD treatment in Parkinson's disease patients consists of topical antifungals, such as ketoconazole, and antiinflammatory agents, including corticosteroids and topical calcineurin inhibitors.
- Systemic antifungals, although effective, should be avoided for the risk of neurological side effects (eg, paresthesia, dysesthesia).
- Since poor hygiene has also been considered among SD predisposing factors in Parkinson subjects, daily cleaning of the affected areas with oil-free detergents is recommended.
View source ↗